Abstract

Advances in the understanding of the molecular pathogenesis of acute myeloid leukemia have led to the identification of diagnostic and prognostic markers, resulting in further refinement of karyotype-based risk classification. This article presents strategies for induction therapy of younger adults and approaches to postremission therapy based on prognostic features. Although some older adults may benefit from intensive chemotherapy and reduced-intensity hematopoietic stem cell transplantation, development...